RS50568B - Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze - Google Patents
Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinazeInfo
- Publication number
- RS50568B RS50568B RSP-2008/0109A RSP20080109A RS50568B RS 50568 B RS50568 B RS 50568B RS P20080109 A RSP20080109 A RS P20080109A RS 50568 B RS50568 B RS 50568B
- Authority
- RS
- Serbia
- Prior art keywords
- optionally substituted
- hydrogen
- ring
- aliphatic
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 102000003989 Aurora kinases Human genes 0.000 title 1
- 108090000433 Aurora kinases Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000008600 mitotic progression Effects 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- 239000001257 hydrogen Substances 0.000 abstract 11
- 125000001931 aliphatic group Chemical group 0.000 abstract 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 150000002431 hydrogen Chemical class 0.000 abstract 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- -1 cycloaliphatic Chemical group 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Small-Scale Networks (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57165304P | 2004-05-14 | 2004-05-14 | |
US61722104P | 2004-10-08 | 2004-10-08 | |
PCT/US2005/016445 WO2005111039A2 (en) | 2004-05-14 | 2005-05-12 | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase |
EP05779921A EP1771450B9 (en) | 2004-05-14 | 2005-05-12 | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase |
Publications (3)
Publication Number | Publication Date |
---|---|
RS50568B true RS50568B (sr) | 2010-05-07 |
RS50568B9 RS50568B9 (sr) | 2019-06-28 |
RS50568B8 RS50568B8 (sr) | 2019-08-30 |
Family
ID=35262144
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20120416A RS52436B (sr) | 2004-05-14 | 2005-05-12 | Jedinjenja i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze |
RS20080109A RS50568B8 (sr) | 2004-05-14 | 2005-05-12 | Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20120416A RS52436B (sr) | 2004-05-14 | 2005-05-12 | Jedinjenja i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze |
Country Status (26)
Country | Link |
---|---|
US (9) | US7572784B2 (sr) |
EP (4) | EP1771450B9 (sr) |
JP (4) | JP4467616B2 (sr) |
KR (3) | KR101748290B1 (sr) |
CN (1) | CN104193750B (sr) |
AR (1) | AR049277A1 (sr) |
AT (1) | ATE381566T1 (sr) |
AU (1) | AU2005243175B2 (sr) |
BR (1) | BRPI0511139B8 (sr) |
CA (1) | CA2565411C (sr) |
CY (2) | CY1108092T1 (sr) |
DE (1) | DE602005003951T4 (sr) |
DK (1) | DK1771450T5 (sr) |
EA (1) | EA012112B1 (sr) |
ES (3) | ES2299080T3 (sr) |
HK (4) | HK1102500A1 (sr) |
HR (2) | HRP20080120T5 (sr) |
IL (1) | IL179063A (sr) |
MX (1) | MXPA06013042A (sr) |
MY (1) | MY139355A (sr) |
NZ (1) | NZ551370A (sr) |
PL (1) | PL1771450T3 (sr) |
PT (2) | PT1905773E (sr) |
RS (2) | RS52436B (sr) |
TW (1) | TWI338688B (sr) |
WO (1) | WO2005111039A2 (sr) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0511139B8 (pt) | 2004-05-14 | 2021-05-25 | Millennium Pharm Inc | compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos |
EP1799684B1 (en) * | 2004-10-04 | 2014-12-03 | Millennium Pharmaceuticals, Inc. | Lactam compounds useful as protein kinase inhibitors |
EP1813609B1 (en) * | 2004-10-29 | 2013-06-19 | Msd K.K. | Novel aminopyridine derivatives having selective aurora-a inhibitory effect |
JP5075624B2 (ja) | 2005-04-28 | 2012-11-21 | 田辺三菱製薬株式会社 | シアノピリジン誘導体及びその医薬としての用途 |
AU2006243000B2 (en) * | 2005-05-05 | 2011-05-26 | Macrophage Pharma Limited | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase |
US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
US20090062302A1 (en) * | 2006-01-24 | 2009-03-05 | Buser-Doepner Carolyn A | Jak2 Tyrosine Kinase Inhibition |
WO2007108936A2 (en) * | 2006-03-15 | 2007-09-27 | Wyeth | N-substituted-azacyclylamines as histamine-3 antagonists |
JP2009530342A (ja) * | 2006-03-20 | 2009-08-27 | エフ.ホフマン−ラ ロシュ アーゲー | Btkおよびsyk蛋白キナーゼを阻害する方法 |
CA2649913A1 (en) * | 2006-05-19 | 2007-11-29 | Wyeth | N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists |
WO2008021038A2 (en) | 2006-08-09 | 2008-02-21 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
PE20081152A1 (es) * | 2006-10-06 | 2008-08-10 | Wyeth Corp | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 |
GEP20135728B (en) | 2006-10-09 | 2013-01-25 | Takeda Pharmaceuticals Co | Kinase inhibitors |
WO2008044045A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2073803B1 (en) | 2006-10-12 | 2018-09-19 | Astex Therapeutics Limited | Pharmaceutical combinations |
CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
AU2012203952B2 (en) * | 2006-11-16 | 2014-12-11 | Millennium Pharmaceuticals, Inc. | Compounds for inhibiting mitotic progression |
AU2014280932B2 (en) * | 2006-11-16 | 2016-10-06 | Millennium Pharmaceuticals, Inc. | Compounds for inhibiting mitotic progression |
PE20090720A1 (es) * | 2007-05-24 | 2009-06-11 | Wyeth Corp | Derivados de azaciclilbenzamida como antagonistas de histamina-3 |
TW200914457A (en) * | 2007-05-31 | 2009-04-01 | Kyowa Hakko Kogyo Kk | Pyrimidodiazepinone derivative |
CL2008002088A1 (es) * | 2007-07-16 | 2008-09-05 | Wyeth Corp | Compuestos derivados de fenilo sustituido, moduladores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de trastornos cognitivos tales como demencia, alzheimer, entre otros. |
EP2185504A2 (en) * | 2007-09-04 | 2010-05-19 | Biolipox AB | Bis-aromatic compounds useful in the treatment of inflammation |
TW200918062A (en) * | 2007-09-12 | 2009-05-01 | Wyeth Corp | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists |
CA2699384A1 (en) * | 2007-09-12 | 2009-03-19 | Wyeth Llc | Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists |
JP2009108036A (ja) * | 2007-09-28 | 2009-05-21 | Fujifilm Corp | 新規アセチレン化合物、その製造方法、それを構成単位として含むポリマー、該化合物及び/又は該ポリマーを含む組成物、該組成物を硬化させてなる硬化物 |
JP5555186B2 (ja) * | 2008-02-29 | 2014-07-23 | クロマ セラピューティクス リミテッド | p38MAPキナーゼ阻害剤 |
GB0803747D0 (en) * | 2008-02-29 | 2008-04-09 | Martin | Enzyme and receptor modulation |
EP2276346B1 (en) | 2008-04-30 | 2016-11-23 | National Health Research Institutes | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors |
US20110112193A1 (en) * | 2008-05-14 | 2011-05-12 | Peter Nilsson | Bis-aryl compounds for use as medicaments |
EP2373657B1 (en) | 2008-12-05 | 2016-09-14 | Millennium Pharmaceuticals, Inc. | 5,7-dihydro-6h-pyrimido[5,4-d][1]benzazepin-6-thiones as plk inhibitors |
WO2010074724A1 (en) | 2008-12-22 | 2010-07-01 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
EP2406223A2 (en) | 2009-03-12 | 2012-01-18 | Biolipox AB | Bis aromatic compounds for use as ltc4 synthase inhibitors |
CN102348686A (zh) | 2009-03-12 | 2012-02-08 | 比奥里波克斯公司 | 用作ltc4合酶抑制剂的双芳族化合物 |
US20120035217A1 (en) | 2009-03-12 | 2012-02-09 | Biolipox Ab | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors |
EP2406220A1 (en) | 2009-03-12 | 2012-01-18 | Biolipox AB | Bis aromatic compounds for use as ltc4 synthase inhibitors |
US8518933B2 (en) | 2009-04-23 | 2013-08-27 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
US8546377B2 (en) * | 2009-04-23 | 2013-10-01 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
JO3434B1 (ar) * | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
RU2012140021A (ru) | 2010-02-19 | 2014-03-27 | Миллениум Фармасьютикалз, Инк. | КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ |
EP2545036A1 (en) | 2010-03-12 | 2013-01-16 | Biolipox AB | Bis aromatic compounds for use as ltc4 synthase inhibitors |
TW201316991A (zh) | 2011-06-03 | 2013-05-01 | Millennium Pharm Inc | Mek抑制劑與奧諾拉(aurora)a激酶選擇性抑制劑之組合 |
GB201202027D0 (en) * | 2012-02-06 | 2012-03-21 | Sareum Ltd | Pharmaceutical compounds |
US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
EP2827869A4 (en) | 2012-03-23 | 2015-09-23 | Dennis Brown | COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO |
CN103804391A (zh) * | 2012-11-01 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
EP2976086B1 (en) | 2013-03-22 | 2020-10-14 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
CN103408552B (zh) * | 2013-07-25 | 2015-07-01 | 苏州明锐医药科技有限公司 | 阿立塞替的制备方法 |
JP6525474B2 (ja) | 2013-12-06 | 2019-06-05 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | オーロラキナーゼ阻害剤と抗cd30抗体の併用 |
WO2017015316A1 (en) * | 2015-07-21 | 2017-01-26 | Millennium Pharmaceuticals, Inc. | Administration of aurora kinase inhibitor and chemotherapeutic agents |
US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
EP3903828A4 (en) | 2018-12-21 | 2022-10-05 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR |
US20220305048A1 (en) | 2019-08-26 | 2022-09-29 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
CN112062768B (zh) * | 2020-07-20 | 2021-08-31 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 具有Aurora激酶降解活性的小分子及其制备方法和应用 |
WO2023113457A1 (ko) * | 2021-12-14 | 2023-06-22 | (주)프레이저테라퓨틱스 | 폴리유비퀴틴화에 의한 표적 단백질 또는 폴리펩티드의 분해용 신규 화합물 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3947585A (en) * | 1974-06-03 | 1976-03-30 | Ciba-Geigy Corporation | Pyrazolobenzazepines |
US4022801A (en) | 1974-06-03 | 1977-05-10 | Ciba-Geigy Corporation | Pyrazolobenzazepines |
US4028381A (en) | 1975-05-05 | 1977-06-07 | Ciba-Geigy Corporation | Pyrazolobenzazepines |
US4099012A (en) * | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
CA1138863A (en) | 1979-02-07 | 1983-01-04 | Norman W. Gilman | Benzazepine-derivatives |
KR840000061B1 (ko) | 1979-02-07 | 1984-01-31 | 에프. 호프만-라 롯슈 앤드 캄파니 아크티엔 게젤샤프트 | 벤즈아제핀 유도체의 제조방법 |
US4547581A (en) | 1979-02-07 | 1985-10-15 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines and intermediates in their preparation |
US4481142A (en) * | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
ZA80492B (en) * | 1979-02-07 | 1981-01-28 | Hoffmann La Roche | Benzazepine derivatives |
US4318854A (en) * | 1979-02-07 | 1982-03-09 | Hoffmann-La Roche Inc. | Intermediates in the production of 2-benzazepines |
US4469633A (en) * | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
NL8102182A (nl) | 1981-05-04 | 1982-12-01 | Philips Nv | Kleurenbeeldbuis. |
EP0273697A3 (en) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-benzazepines with 5- and 6- membered heterocyclic rings |
US5166151A (en) * | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
US5210082A (en) * | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
US5747487A (en) | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
EP0888350A1 (en) | 1996-03-08 | 1999-01-07 | Zeneca Limited | Azolobenzazepine derivatives as neurologically active agents |
EP0946523A1 (en) | 1996-12-23 | 1999-10-06 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
PL339544A1 (en) | 1997-09-29 | 2000-12-18 | Meiji Seika Kaisha | Tricyclic derivatives of thiazolobenzazepin, method of obtaining them antillergic agents |
US6277844B1 (en) * | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
AU4841700A (en) | 1999-05-12 | 2000-11-21 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
MXPA03002294A (es) * | 2000-09-15 | 2005-09-08 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de proteina cinasa. |
EP1345922B1 (en) * | 2000-12-21 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
BR0211729A (pt) | 2001-08-09 | 2004-08-24 | Actelion Pharmaceuticals Ltd | Compostos, composições farmacêuticas, processo para fabricar compostos, uso de um ou mais compostos, e, processo para fabricar composições farmacêuticas |
CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
BRPI0511139B8 (pt) * | 2004-05-14 | 2021-05-25 | Millennium Pharm Inc | compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos |
JP2008520713A (ja) | 2004-11-17 | 2008-06-19 | ミイカナ セラピューティクス インコーポレイテッド | キナーゼ阻害剤 |
WO2006070198A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
US20090203671A1 (en) | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
JO3434B1 (ar) * | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
-
2005
- 2005-05-12 BR BRPI0511139A patent/BRPI0511139B8/pt active IP Right Grant
- 2005-05-12 KR KR1020137013571A patent/KR101748290B1/ko active IP Right Grant
- 2005-05-12 PT PT07024446T patent/PT1905773E/pt unknown
- 2005-05-12 ES ES05779921T patent/ES2299080T3/es active Active
- 2005-05-12 EP EP05779921A patent/EP1771450B9/en active Active
- 2005-05-12 CN CN201410345955.0A patent/CN104193750B/zh active Active
- 2005-05-12 NZ NZ551370A patent/NZ551370A/en unknown
- 2005-05-12 JP JP2007513304A patent/JP4467616B2/ja active Active
- 2005-05-12 EA EA200602100A patent/EA012112B1/ru not_active IP Right Cessation
- 2005-05-12 EP EP10178391.8A patent/EP2261226B1/en active Active
- 2005-05-12 DE DE602005003951T patent/DE602005003951T4/de active Active
- 2005-05-12 MX MXPA06013042A patent/MXPA06013042A/es active IP Right Grant
- 2005-05-12 KR KR1020067026332A patent/KR101792651B1/ko active IP Right Grant
- 2005-05-12 MY MYPI20052151A patent/MY139355A/en unknown
- 2005-05-12 RS RS20120416A patent/RS52436B/sr unknown
- 2005-05-12 CA CA2565411A patent/CA2565411C/en active Active
- 2005-05-12 PL PL05779921T patent/PL1771450T3/pl unknown
- 2005-05-12 AU AU2005243175A patent/AU2005243175B2/en active Active
- 2005-05-12 WO PCT/US2005/016445 patent/WO2005111039A2/en active Application Filing
- 2005-05-12 DK DK05779921.5T patent/DK1771450T5/da active
- 2005-05-12 ES ES07024446T patent/ES2391577T3/es active Active
- 2005-05-12 EP EP13189940.3A patent/EP2746285B1/en active Active
- 2005-05-12 KR KR1020127014200A patent/KR20120091275A/ko active Search and Examination
- 2005-05-12 PT PT05779921T patent/PT1771450E/pt unknown
- 2005-05-12 RS RS20080109A patent/RS50568B8/sr unknown
- 2005-05-12 ES ES10178391.8T patent/ES2540987T3/es active Active
- 2005-05-12 EP EP13189935.3A patent/EP2719698B1/en active Active
- 2005-05-12 US US11/127,855 patent/US7572784B2/en active Active
- 2005-05-12 AT AT05779921T patent/ATE381566T1/de active
- 2005-05-13 TW TW094115612A patent/TWI338688B/zh active
- 2005-05-16 AR ARP050102001A patent/AR049277A1/es unknown
-
2006
- 2006-11-06 IL IL179063A patent/IL179063A/en active IP Right Grant
- 2006-12-21 US US11/643,600 patent/US20070185087A1/en not_active Abandoned
-
2007
- 2007-10-03 HK HK07110701A patent/HK1102500A1/xx unknown
-
2008
- 2008-03-17 CY CY20081100297T patent/CY1108092T1/el unknown
- 2008-03-19 HR HRP20080120TT patent/HRP20080120T5/hr unknown
- 2008-05-08 JP JP2008122788A patent/JP5148358B2/ja active Active
- 2008-09-18 HK HK08110327.5A patent/HK1114853A1/xx unknown
-
2009
- 2009-05-27 US US12/472,583 patent/US8399659B2/en active Active
-
2011
- 2011-09-16 JP JP2011203714A patent/JP2012006972A/ja not_active Withdrawn
-
2012
- 2012-10-02 HR HRP20120785TT patent/HRP20120785T1/hr unknown
- 2012-10-03 US US13/644,216 patent/US9102678B2/en active Active
- 2012-10-16 CY CY20121100962T patent/CY1113192T1/el unknown
-
2014
- 2014-02-14 JP JP2014026015A patent/JP5827708B2/ja active Active
- 2014-12-23 HK HK14112844.7A patent/HK1199254A1/xx unknown
-
2015
- 2015-06-08 HK HK15105404.2A patent/HK1205102A1/xx unknown
- 2015-07-27 US US14/810,225 patent/US9765078B2/en active Active
-
2017
- 2017-09-18 US US15/707,484 patent/US10414770B2/en active Active
-
2019
- 2019-09-13 US US16/569,809 patent/US11014928B2/en active Active
-
2021
- 2021-05-24 US US17/328,618 patent/US20220041605A1/en not_active Abandoned
-
2023
- 2023-10-19 US US18/490,596 patent/US20240083906A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS50568B (sr) | Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze | |
RS53734B1 (sr) | Inhibitori iap | |
RS53788B1 (sr) | Jedinjenje za inhibiciju mitotičke progresije | |
RS52326B (sr) | Fenil-piperazin derivati kao inhibitori resorbcije serotonina | |
ME00411B (me) | Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavistan od natrijuma | |
HRP20080022T3 (en) | Pyrrolopyridine derivatives and their use as crth2 antagonists | |
RS52927B (sr) | Postupak lečenja ili profilakse | |
RS51471B (sr) | Derivati bifeniloksisirćetne kiseline za tretman bolesti dišnog trakta | |
HUP0003921A2 (hu) | VLA-4 által közvetített leukocitaadhéziót gátló szulfonilezett dipeptidszármazékok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
HUP0100950A2 (hu) | Ciklusos aminovegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények | |
RS52702B (sr) | Jedinjenja karbazola i terapeutske upotrebe jedinjenja | |
HRP20000854B1 (en) | Therapeutic biaryl derivatives | |
EA200600509A1 (ru) | Соединения пиримидотиофена | |
EA200900358A1 (ru) | Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv | |
RS52137B (sr) | Nova heterociklična jedinjenja aktivna kao inhibitori beta-laktamaze | |
RU2006134003A (ru) | Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
TW200745029A (en) | Sulfonamide derivatives exhibiting PGD2 receptor antagonism | |
RS52883B (sr) | Heterociklični inhibitori aspartil proteaze | |
NO20053246L (no) | Kondensert 1,3-dihydroimidazol-ringforbindelse. | |
NO20090952L (no) | N-(aminoheteroaryl) - lh - indol-2-karboksamidderivater og fremstilling og terapeutisk anvendelse derav | |
RS50045B (sr) | Aktivatori glukokinaze | |
RS50214B (sr) | Nova heterociklična jedinjenja, njihovo dobijanje i njihova upotreba kao medikamenata, a naročito kao anti-bakterijskih agenasa | |
JP2009518317A5 (sr) | ||
EA200300558A1 (ru) | Агонисты альфа-рецепторов, активируемых пролифератором пероксисомы | |
AR025386A1 (es) | Moduladores de los receptores activados del proliferador de peroxisomas |